IDEAS home Printed from https://ideas.repec.org/f/phu379.html
   My authors  Follow this author

Don Husereau

Personal Details

First Name:Don
Middle Name:
Last Name:Husereau
Suffix:
RePEc Short-ID:phu379
http://www.linkedin.com/pub/don-husereau/6/841/ba1

Research output

as
Jump to: Articles

Articles

  1. Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder, 2013. "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement," PharmacoEconomics, Springer, vol. 31(5), pages 361-367, May.
  2. Ake Blomqvist & Colin Busby & Don Husereau, 2013. "Capturing Value from Health Technologies in Lean Times," C.D. Howe Institute Commentary, C.D. Howe Institute, issue 396, December.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Articles

  1. Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder, 2013. "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement," PharmacoEconomics, Springer, vol. 31(5), pages 361-367, May.

    Cited by:

    1. Dyfrig Hughes & Joanna Charles & Dalia Dawoud & Rhiannon Tudor Edwards & Emily Holmes & Carys Jones & Paul Parham & Catrin Plumpton & Colin Ridyard & Huw Lloyd-Williams & Eifiona Wood & Seow Tien Yeo, 2016. "Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches," PharmacoEconomics, Springer, vol. 34(5), pages 447-461, May.
    2. Patrick Zueger & Neil Schultz & Todd Lee, 2014. "Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review," PharmacoEconomics, Springer, vol. 32(11), pages 1079-1091, November.
    3. Matthew Calver, 2016. "Measuring the Appropriate Outcomes for Better Decision-Making: A Framework to Guide the Analysis of Health Policy," CSLS Research Reports 2016-03, Centre for the Study of Living Standards.
    4. George A. K. Voorn & Pepijn Vemer & Dominique Hamerlijnck & Isaac Corro Ramos & Geertruida J. Teunissen & Maiwenn Al & Talitha L. Feenstra, 2016. "The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling," Applied Health Economics and Health Policy, Springer, vol. 14(2), pages 129-133, April.
    5. Luis Hernandez & Asli Ozen & Rodrigo DosSantos & Denis Getsios, 2016. "Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease," PharmacoEconomics, Springer, vol. 34(7), pages 681-707, July.
    6. Darren K. Burns & Edward C. F. Wilson & Paula Browne & Sandra Olive & Allan Clark & Penny Galey & Emma Dix & Helene Woodhouse & Sue Robinson & Andrew Wilson, 2016. "The Cost Effectiveness of Maintenance Schedules Following Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: An Economic Evaluation Alongside a Randomised Controlled Tria," Applied Health Economics and Health Policy, Springer, vol. 14(1), pages 105-115, February.
    7. Garret S. Christensen & Edward Miguel, 2016. "Transparency, Reproducibility, and the Credibility of Economics Research," NBER Working Papers 22989, National Bureau of Economic Research, Inc.
    8. Simon van der Schans & Lucas M. A. Goossens & Melinde R. S. Boland & Janwillem W. H. Kocks & Maarten J. Postma & Job F. M. van Boven & Maureen P. M. H. Rutten-van Mölken, 2017. "Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendatio," PharmacoEconomics, Springer, vol. 35(1), pages 43-63, January.
    9. Syed Mohiuddin, 2014. "A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder," Applied Health Economics and Health Policy, Springer, vol. 12(4), pages 359-372, August.
    10. Feng Xie & A. Pickard & Paul Krabbe & Dennis Revicki & Rosalie Viney & Nancy Devlin & David Feeny, 2015. "A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)," PharmacoEconomics, Springer, vol. 33(8), pages 867-877, August.
    11. Gregory Merlo & Katie Page & Julie Ratcliffe & Kate Halton & Nicholas Graves, 2015. "Bridging the Gap: Exploring the Barriers to Using Economic Evidence in Healthcare Decision Making and Strategies for Improving Uptake," Applied Health Economics and Health Policy, Springer, vol. 13(3), pages 303-309, June.
    12. Pieter T. Boer & Geert W. J. Frederix & Talitha L. Feenstra & Pepijn Vemer, 2016. "Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer," PharmacoEconomics, Springer, vol. 34(9), pages 833-845, September.
    13. Jagpreet Chhatwal & Tianhua He & Maria A. Lopez-Olivo, 2016. "Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals," PharmacoEconomics, Springer, vol. 34(6), pages 551-567, June.
    14. Jonathan Karnon, 2016. "Model Validation: Has it’s Time Come?," PharmacoEconomics, Springer, vol. 34(9), pages 829-831, September.
    15. Melina Dritsaki & Felix Achana & James Mason & Stavros Petrou, 2017. "Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Sys," PharmacoEconomics, Springer, vol. 35(5), pages 501-515, May.
    16. Alyson Mahar & Abraham El-Sedfy & Savtaj Brar & Ana Johnson & Natalie Coburn, 2015. "Are We Lacking Economic Evaluations in Gastric Cancer Treatment?," PharmacoEconomics, Springer, vol. 33(2), pages 83-87, February.
    17. Nadia YAKHELEF & Martine AUDIBERT & Bruno PEIRERA & Antoine MONS & Emmanuel CHABERT, 2015. "Cost-utility Analysis of Vertebroplasty versus Thoracolumbosacral Orthosis in the Treatment of Traumatic Vertebral Fractures," Working Papers 201534, CERDI.
    18. Mickaël Hiligsmann & Silvia Evers & Wafa Ben Sedrine & John Kanis & Bram Ramaekers & Jean-Yves Reginster & Stuart Silverman & Caroline Wyers & Annelies Boonen, 2015. "A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis," PharmacoEconomics, Springer, vol. 33(3), pages 205-224, March.
    19. Manal H. El-Hamamsy & Gihan H. Elsisi & Randa Eldessouki & Mohamed M. Elmazar & Ahmed S. Taha & Basma F. Awad & Hossam Elmansy, 2016. "Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus Warfarin Alone in Mechanical Valve Prostheses," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 431-440, August.
    20. Shankar Prinja & Akashdeep Chauhan & Blake Angell & Indrani Gupta & Stephen Jan, 2015. "A Systematic Review of the State of Economic Evaluation for Health Care in India," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 595-613, December.
    21. Simon Frey & Carl R. Blankart & Tom Stargardt, 2016. "Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature," PharmacoEconomics, Springer, vol. 34(5), pages 479-498, May.
    22. Andrea Iannaccone & Thomas Marwick, 2015. "Cost Effectiveness of Transcatheter Aortic Valve Replacement Compared with Medical Management or Surgery for Patients with Aortic Stenosis," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 29-45, February.
    23. Laura Pizzi & Neil Seligman & Jason Baxter & Eric Jutkowitz & Vincenzo Berghella, 2014. "Cost and Cost Effectiveness of Vaginal Progesterone Gel in Reducing Preterm Birth: An Economic Analysis of the PREGNANT Trial," PharmacoEconomics, Springer, vol. 32(5), pages 467-478, May.
    24. Rachel Elliott & Koen Putman & James Davies & Lieven Annemans, 2014. "A Review of the Methodological Challenges in Assessing the Cost Effectiveness of Pharmacist Interventions," PharmacoEconomics, Springer, vol. 32(12), pages 1185-1199, December.
    25. Pepijn Vemer & Maureen Rutten-van Mölken, 2013. "The Road Not Taken: Transferability Issues in Multinational Trials," PharmacoEconomics, Springer, vol. 31(10), pages 863-876, October.
    26. Neily Zakiyah & Maarten Postma & Philip Baker & Antoinette Asselt, 2015. "Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic Assessments," PharmacoEconomics, Springer, vol. 33(10), pages 1069-1082, October.
    27. Caroline M. Vass & Katherine Payne, 2017. "Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet?," PharmacoEconomics, Springer, vol. 35(9), pages 859-866, September.
    28. James Buchanan & Sarah Wordsworth & Ruth Clifford & Pauline Robbe & Jenny C. Taylor & Anna Schuh & Samantha J. L. Knight, 2017. "Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(8), pages 845-858, August.
    29. Jinsong Geng & Hao Yu & Yiwei Mao & Peng Zhang & Yingyao Chen, 2015. "Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes," PharmacoEconomics, Springer, vol. 33(6), pages 581-597, June.
    30. Marije Oosterhoff & Marloes E. Maas & Lotte M. G. Steuten, 2016. "A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers," Applied Health Economics and Health Policy, Springer, vol. 14(1), pages 51-65, February.
    31. Marita Mann & Assegid Mengistu & Johannes Gaeseb & Evans Sagwa & Greatjoy Mazibuko & Joseph B. Babigumira & Louis P. Garrison & Andy Stergachis, 2016. "Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost–Utility Analysis," Drug Safety, Springer, vol. 39(9), pages 859-872, September.
    32. Helen Weatherly & Rita Faria & Bernard Van den Berg & Mark Sculpher & Peter O’Neill & Kay Nolan & Julie Glanville & Jaana Isojarvi & Erin Baragula & Mary Edwards, 2017. "Scoping review on social care economic evaluation methods," Working Papers 150cherp, Centre for Health Economics, University of York.
    33. Fred Hellinger, 2013. "Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US," PharmacoEconomics, Springer, vol. 31(12), pages 1091-1104, December.
    34. Daisuke Goto & Ya-Chen Tina Shih & Pascal Lecomte & Melvin Olson & Chukwukadibia Udeze & Yujin Park & C. Daniel Mullins, 2017. "Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(7), pages 685-695, July.
    35. Edward Wilson & Ludmila Shulgina & Anthony Cahn & Edwin Chilvers & Helen Parfrey & Allan Clark & Orion Twentyman & Andrew Wilson, 2014. "Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole: An Economic Evaluation Alongside a Randomised Controlled Trial," PharmacoEconomics, Springer, vol. 32(1), pages 87-99, January.
    36. Ana Teresa Paquete & Luís Silva Miguel & Ursula Becker & Catarina Pereira & Carlos Gouveia Pinto, 2017. "Cost‐Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy," Applied Health Economics and Health Policy, Springer, vol. 15(4), pages 501-512, August.
    37. Hedwig Blommestein & Margreet Franken & Carin Uyl-de Groot, 2015. "A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry," PharmacoEconomics, Springer, vol. 33(6), pages 551-560, June.
    38. Stéphane Verguet & Jane J. Kim & Dean T. Jamison, 2016. "Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial," PharmacoEconomics, Springer, vol. 34(9), pages 913-923, September.
    39. Rachel Elliott & Koen Putman & Matthew Franklin & Lieven Annemans & Nick Verhaeghe & Martin Eden & Jasdeep Hayre & Sarah Rodgers & Aziz Sheikh & Anthony Avery, 2014. "Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)," PharmacoEconomics, Springer, vol. 32(6), pages 573-590, June.
    40. Xinyang Hua & Thomas Wai-Chun Lung & Andrew Palmer & Lei Si & William H. Herman & Philip Clarke, 2017. "How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review," PharmacoEconomics, Springer, vol. 35(3), pages 319-329, March.
    41. Paul Tappenden & James Chilcott, 2014. "Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models," PharmacoEconomics, Springer, vol. 32(10), pages 967-979, October.
    42. Andrew Gawron & Dustin French & John Pandolfino & Colin Howden, 2014. "Economic Evaluations of Gastroesophageal Reflux Disease Medical Management," PharmacoEconomics, Springer, vol. 32(8), pages 745-758, August.
    43. Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder, 2013. "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement," PharmacoEconomics, Springer, vol. 31(5), pages 361-367, May.
    44. Praveen Thokala & Simon Dixon & Beate Jahn, 2015. "Resource Modelling: The Missing Piece of the HTA Jigsaw?," PharmacoEconomics, Springer, vol. 33(3), pages 193-203, March.
    45. Francisco Jódar-Sánchez & Amaia Malet-Larrea & José Martín & Leticia García-Mochón & M. López del Amo & Fernando Martínez-Martínez & Miguel Gastelurrutia-Garralda & Victoria García-Cárdenas & Daniel S, 2015. "Cost-Utility Analysis of a Medication Review with Follow-Up Service for Older Adults with Polypharmacy in Community Pharmacies in Spain: The conSIGUE Program," PharmacoEconomics, Springer, vol. 33(6), pages 599-610, June.
    46. Nadia Yakhelef & Martine Audibert & Bruno Peirera & Antoine Mons & Emmanuel Chabert, 2015. "Cost-utility Analysis of Vertebroplasty versus Thoracolumbosacral Orthosis in the Treatment of Traumatic Vertebral Fractures," Working Papers halshs-01241824, HAL.
    47. Sabrina Storgaard Sørensen & Kjeld Møller Pedersen & Ulla Møller Weinreich & Lars Ehlers, 2017. "Economic Evaluation of Community-Based Case Management of Patients Suffering From Chronic Obstructive Pulmonary Disease," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 413-424, June.
    48. Jonathon Campbell & Thenuga Sasitharan & Fawziah Marra, 2015. "A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection," Applied Health Economics and Health Policy, Springer, vol. 13(4), pages 325-340, August.
    49. Gerardus Frederix & Hossein Haji Ali Afzali & Erik Dasbach & Robyn Ward, 2015. "Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions," PharmacoEconomics, Springer, vol. 33(8), pages 777-781, August.
    50. Stavros Petrou & Kamran Khan, 2013. "An Overview of the Health Economic Implications of Elective Caesarean Section," Applied Health Economics and Health Policy, Springer, vol. 11(6), pages 561-576, December.
    51. Christopher James Sampson & Tim Wrightson, 2017. "Model Registration: A Call to Action," PharmacoEconomics - Open, Springer, vol. 1(2), pages 73-77, June.
    52. Cynthia P. Iglesias & Alexander Thompson & Wolf H. Rogowski & Katherine Payne, 2016. "Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations," PharmacoEconomics, Springer, vol. 34(11), pages 1161-1172, November.
    53. Yoko Laurence & Ulla Griffiths & Anna Vassall, 2015. "Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review," PharmacoEconomics, Springer, vol. 33(9), pages 939-955, September.
    54. Asrul Akmal Shafie & Chin Hui Ng & Yui Ping Tan & Nathorn Chaiyakunapruk, 2017. "Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus," PharmacoEconomics, Springer, vol. 35(2), pages 141-162, February.
    55. Steffen Flessa & Dominik Dietz & Elisabete Weiderpass, 2016. "Health policy support under extreme uncertainty: the case of cervical cancer in Cambodia," EURO Journal on Decision Processes, Springer;EURO - The Association of European Operational Research Societies, vol. 4(3), pages 183-218, November.
    56. Laura Burgers & William Redekop & Johan Severens, 2014. "Challenges in Modelling the Cost Effectiveness of Various Interventions for Cardiovascular Disease," PharmacoEconomics, Springer, vol. 32(7), pages 627-637, July.
    57. Ben Kearns & Roberta Ara & Allan Wailoo & Andrea Manca & Monica Alava & Keith Abrams & Mike Campbell, 2013. "Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations," PharmacoEconomics, Springer, vol. 31(8), pages 643-652, August.
    58. J. Caro & Jörgen Möller, 2014. "Decision-Analytic Models: Current Methodological Challenges," PharmacoEconomics, Springer, vol. 32(10), pages 943-950, October.
    59. Maximilian Hatz & Reiner Leidl & Nichola Yates & Björn Stollenwerk, 2014. "A Systematic Review of the Quality of Economic Models Comparing Thrombosis Inhibitors in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention," PharmacoEconomics, Springer, vol. 32(4), pages 377-393, April.
    60. Catrin O. Plumpton & Daniel Roberts & Munir Pirmohamed & Dyfrig A. Hughes, 2016. "A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions," PharmacoEconomics, Springer, vol. 34(8), pages 771-793, August.
    61. Stuart Wright & Cheryl Jones & Katherine Payne & Nimarta Dharni & Fiona Ulph, 2015. "The Role of Information Provision in Economic Evaluations of Newborn Bloodspot Screening: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 615-626, December.
    62. Kittiphong Thiboonboon & Benjarin Santatiwongchai & Varit Chantarastapornchit & Waranya Rattanavipapong & Yot Teerawattananon, 2016. "A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines," Applied Health Economics and Health Policy, Springer, vol. 14(6), pages 659-672, December.
    63. Sabina Sanghera & Emma Frew & Janesh Gupta & Joe Kai & Tracy Roberts, 2015. "Exploring the Use of Cost-Benefit Analysis to Compare Pharmaceutical Treatments for Menorrhagia," PharmacoEconomics, Springer, vol. 33(9), pages 957-965, September.
    64. Kinchin, Irina & Jacups, Susan & Hunter, Gary & Rogerson, Bernadette, 2016. "Economic evaluation of ‘Return to Country’: A remote Australian initiative to address indigenous homelessness," Evaluation and Program Planning, Elsevier, vol. 56(C), pages 69-75.
    65. Don Husereau & Michael Drummond & Stavros Petrou & Dan Greenberg & Josephine Mauskopf & Federico Augustovski & Andrew Briggs & David Moher & Elizabeth Loder & Chris Carswell, 2015. "Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration," PharmacoEconomics, Springer, vol. 33(5), pages 535-536, May.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Don Husereau should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.